Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
Développer la qualité dans le champ sanitaire, social et médico-social
Logo
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Établissements de santé

2 results

  • Active substance : daclizumab
Filter
Topic
  • Diagnostic and therapeutic techniques (2)
  • Plus ...
    • Transfusions, transplantations (1)
    • Drug therapy (1)
    • Surgical procedures (1)
    • Plus ...
      • Gastrointestinal surgery (1)
  • Diseases and conditions (2)
  • Plus ...
    • Nervous system diseases (1)
    • Plus ...
      • Central nervous system diseases (1)
      • Demyelinating diseases (1)
    • Digestive system diseases (1)
    • Plus ...
      • Pancreatic and biliary tract diseases (1)
    • Endocrine system and metabolic diseases (1)
    • Plus ...
      • Diabetes mellitus (1)
    • Immune system diseases (1)
    • Plus ...
      • Autoimmune diseases (1)
Content type
  • Drugs, devices and medical acts (2)
  • Plus ...
    • Medicine (1)
    • Health technology assessment (1)
Fabricant
  • inconnu (1)
Langue
  • Français (2)
Substance active
  • albumine humaine (1)
  • alcool (1)
  • argent (1)
  • daclizumab (2)
  • prednisolone (1)
  • sirolimus (1)
  • tacrolimus (1)
More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 2 results

  • Pancreatic islet transplantation - INAHTA Brief

    Health technology assessment - Posted on 20/7/2020
    Download document
    Add to my selection

  • ZINBRYTA (daclizumab)

    Medicine - Posted on 16/2/2018 - Mis à jour le 12/6/2019
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
MmjJSeF0C1mCePxB